Search research articles
Contact Us
Filters
Showing results (11-20 of 251) with videos related to
Page
of 26
Sort By:
Clinical and Experimental Rheumatology
|
March 20, 1999
The combination of methotrexate, sulfasalazine and hydroxychloroquine is highly effective in rheumatoid arthritis
D E Furst
Seminars in Arthritis and Rheumatism
|
October 1, 1993
Comparing the strengths and weaknesses of observational and experimental studies using a postmarketing surveillance study as a protypic example
D E Furst
Lupus
|
June 1, 1996
Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases
D E Furst
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases
|
December 17, 2008
Perspectives on the cyclooxygenase-2/ cyclooxygenase-1 hypothesis
D E Furst
The Journal of Rheumatology
|
February 1, 1991
Defining the toxicity of disease modifying antirheumatic drugs in rheumatoid arthritis
D E Furst
Drugs
|
January 1, 1990
Rational use of disease-modifying antirheumatic drugs
D E Furst
Lancet (London, England)
|
August 30, 2000
Aggressive strategies for treating aggressive rheumatoid arthritis: has the case been proven?
D E Furst
Current Opinion in Rheumatology
|
November 25, 2000
Rational therapy in the treatment of systemic sclerosis
D E Furst
Current Rheumatology Reports
|
December 21, 2000
Oligo- and monoarticular inflammatory arthritis: a need and a hope
D E Furst
The Journal of Rheumatology. Supplement
|
April 1, 1992
Toxicity of antirheumatic medications in children with juvenile arthritis
D E Furst
Page
of 26
Search research articles
Search
Showing results (11-20 of 251) with videos related to
Sort By:
Page
of 26
Clinical and Experimental Rheumatology
|
March 20, 1999
The combination of methotrexate, sulfasalazine and hydroxychloroquine is highly effective in rheumatoid arthritis
D E Furst
Seminars in Arthritis and Rheumatism
|
October 1, 1993
Comparing the strengths and weaknesses of observational and experimental studies using a postmarketing surveillance study as a protypic example
D E Furst
Lupus
|
June 1, 1996
Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases
D E Furst
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases
|
December 17, 2008
Perspectives on the cyclooxygenase-2/ cyclooxygenase-1 hypothesis
D E Furst
The Journal of Rheumatology
|
February 1, 1991
Defining the toxicity of disease modifying antirheumatic drugs in rheumatoid arthritis
D E Furst
Drugs
|
January 1, 1990
Rational use of disease-modifying antirheumatic drugs
D E Furst
Lancet (London, England)
|
August 30, 2000
Aggressive strategies for treating aggressive rheumatoid arthritis: has the case been proven?
D E Furst
Current Opinion in Rheumatology
|
November 25, 2000
Rational therapy in the treatment of systemic sclerosis
D E Furst
Current Rheumatology Reports
|
December 21, 2000
Oligo- and monoarticular inflammatory arthritis: a need and a hope
D E Furst
The Journal of Rheumatology. Supplement
|
April 1, 1992
Toxicity of antirheumatic medications in children with juvenile arthritis
D E Furst
Page
of 26